PAD 133 (Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 7.5 mg)
Pill imprint PAD 133 has been identified as Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 7.5 mg.
Hydrochlorothiazide/moexipril is used in the treatment of high blood pressure and belongs to the drug class antihypertensive combinations. There is positive evidence of human fetal risk during pregnancy. Hydrochlorothiazide/moexipril 12.5 mg / 7.5 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for PAD 133 (Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 7.5 mg)
- 12.5 mg / 7.5 mg
- Elliptical / Oval
- Prescription only
- Drug Class:
- Antihypertensive combinations
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Paddock Laboratories, Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
polyethylene glycol 400
ferric oxide red
Hydrochlorothiazide and moexipril hydrochloride is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...